Drug Target Review

JULY 5, 2023

A good introduction to the use of CHO cells for biotherapeutics production can be found in an article commemorating the 20th anniversary of the approval of a product produced using CHO cells. These sites are typically in areas of open chromatin and associated with highly expressed genes.

Engineering 106

Engineering DNA Laboratories Production 106

Sygnature Discovery

SEPTEMBER 11, 2024

We’ve successfully tackled targets for: Unprecedented membrane proteins Intrinsically disordered proteins Refolding from inclusion bodies Large protein complexes Labelled proteins for NMR studies RNA structures by crystallography Across our capabilities Protein Expression & Purification Vast diversity of proteins produced.

Science 52

Science Compound Screening Protein Expression RNA 52

Codon

DECEMBER 10, 2023

Predictive models for biology will span all scales, from individual proteins to the culture conditions in which cells grow. Large-scale experiments suggest that <50% of bacterial proteins and <15% of non-bacterial proteins express within E. coli , yeast, and other types of organisms.

Protein Expression 81

Protein Expression Laboratories DNA Engineering 81

The Pharma Data

NOVEMBER 26, 2020

NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A.,

Disease 52

Disease Treatment Clinical Trials FDA 52

Drug Target Review

SEPTEMBER 10, 2024

For example, tox material from a pool of clones will contain a potentially broader profile of product quality attributes (eg glycan profile, high molecular weight species, etc) in addition to potentially slightly higher relative amounts of process impurities which can resemble the worst-case scenario during the toxicology testing.

Drug Development 65

Drug Development Clinical Supply Production FDA 65

Sygnature Discovery

APRIL 26, 2022

Sygnature have acquired Peak Proteins Ltd. Following an extensive partnership between the two companies, this deal will enable seamless integration of protein production and related structure determination projects within Sygnature. The Peak Proteins leadership team will also remain with the business.

Fragment Screening 40

Fragment Screening Protein Production Protein Expression Production 40

The Pharma Data

MAY 2, 2022

The target of DF7001 is 5T4, a protein expressed on cancer cells and stromal cells that support tumor growth associated with poor prognosis in several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck squamous cell carcinomas (HNSCC). View the full release here: [link].

Licensing 52

Licensing Licensing Research Protein Expression 52

The Pharma Data

DECEMBER 8, 2020

Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. The products are used to treat substance use disorder, opioid use disorders and chronic insomnia, respectively. Sigilon Therapeutics .

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

DECEMBER 29, 2020

NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

The Pharma Data

AUGUST 16, 2021

The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation RNA-technology for different targets in the field of infectious diseases.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Broad Institute

AUGUST 24, 2022

The team then conducted analyses that triangulated treatment response, chromosomal deletion or gain, and concordant decreases or increases in mRNA and protein expression. Of the hundreds of genes deleted in this location, the DNA ligase gene LIG1 was one of the mostly consistently suppressed genes at both the mRNA and protein level.

DNA 52

DNA Treatment Protein Expression Protein Production 52

Alta Sciences

APRIL 17, 2024

Our preclinical and bioanalytical experts have extensive experience in leading-edge technologies to support sponsors in the advancement of their gene therapy products. Gene Therapy resources Watch our on-demand webinar, “ Nonclinical Safety Assessment for Gene Therapy Products ”.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

APRIL 26, 2022

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Target Review

MAY 4, 2023

Using GWAS, scientists identified areas of the genome important for producing fetal haemoglobin, a target based on its promise for reversing sickle cell anaemia, but they did not know which exact variant drives its production.

Disease 52

Disease Small Molecule Protein Expression Research 52

The Pharma Data

OCTOBER 28, 2020

In almost all cases of Angelman syndrome, the maternal UBE3A allele is either missing or mutated, resulting in limited to no protein expression. Angelman syndrome is not a degenerative disorder, but the loss of the UBE3A protein expression in neurons results in abnormal communications between neurons. About Ultragenyx.

Protein Expression 40

Protein Expression Therapies Treatment Disease 40

The Pharma Data

SEPTEMBER 10, 2020

Roche’s Chief Medical Officer and Head of Global Product Development. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved.

Treatment 52

Treatment Disease FDA Approval Clinical Trials 52

The Pharma Data

APRIL 8, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. “We EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier designed to treat SMA by increasing production of the survival of motor neuron (SMN) protein. P14: Clinical Trials, Surveys, and Studies in Movement Disorders. About EVRYSDI (risdiplam).

Clinical Trials 52

Clinical Trials Trials Disease Therapies 52

The Pharma Data

SEPTEMBER 8, 2020

Roche’s Chief Medical Officer and Head of Global Product Development. “In Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved.

Clinical Trials 52

Clinical Trials Trials Disease FDA Approval 52

The Pharma Data

SEPTEMBER 2, 2020

Roche’s Chief Medical Officer and Head of Global Product Development. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved.

Clinical Trials 52

Clinical Trials Treatment Disease Therapies 52

Drug Target Review

JANUARY 26, 2024

To test whether the mouse-made human ACE2 proteins were functional, the researchers used numerous methods, which included demonstrating that a psuedovirus containing the Covid spike protein could bind to the receptors and infect cells. This study was published in Virology. Reference 1 Fan S, Ge J, Lan J, et al.

Production 115

Production DNA Virus Protein Expression 115

Drug Target Review

MARCH 15, 2024

Advancements in cell line development (CLD), including screening and selection of final clones, scale up, automation and digitalisation have enabled precision and enhanced productivity. Efforts have focused on Chinese hamster ovary (CHO) cell line improvements since it is a commonly used host for the expression of therapeutic proteins.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform.

Protein Expression 52

Protein Expression Protein Production Production Drug Development 52

The Pharma Data

DECEMBER 3, 2020

protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological Na V 1.1 These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. .–( BUSINESS WIRE )– Stoke Therapeutics , Inc.

Clinical Trials 52

Clinical Trials Protein Expression Pharmacokinetics Trials 52

Drug Target Review

SEPTEMBER 4, 2023

Studies have shown that targeting some expression gene sites could lead to the production of new drugs as indicated. Specific examples: In the African Trypanosmome, the variable surface glycoprotein enables the parasite, to escape the host’s immune reaction and research could help us understand the biological processes.

Drugs 111

Drugs RNA DNA Disease 111

Drug Target Review

MAY 22, 2024

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1

Therapies 59

Therapies RNA Protein Expression DNA 59

Advarra

JANUARY 11, 2024

mRNA Cancer Vaccines mRNA cancer vaccines represent a newer class of vaccines utilizing mRNA’s ability to encode for almost any protein, while maintaining an acceptable safety profile with flexible delivery and production processes. Only after these trials are successful can sponsors seek market approval for mRNA-based products.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

The Pharma Data

SEPTEMBER 28, 2021

In addition, results from Part 1 of Study SRP-9001-102, an ongoing, randomised, double-blind, placebo-controlled clinical test evaluating the security , efficacy, and tolerability of one dose of SRP-9001 in 41 boys with DMD, showed that the study met its primary biological endpoint of change in micro-dystrophin protein expression from baseline.

Clinical Trials 52

Clinical Trials Protein Expression Therapies FDA 52

Elrig

JUNE 13, 2024

TPS advances state-of-the-art science through international forums, workshops, networking opportunities and symposia that promote communication, cooperation, and collaboration among scientists involved in the study of proteins. The foundation of the Society is its flagshipProtein Sciencejournal.

Science 52

Science Protein Expression Drugs International 52

The Pharma Data

JULY 21, 2021

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi , the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

The Pharma Data

SEPTEMBER 22, 2020

About Zolgensma ® ( onasemnogene abeparvovec ) Zolgensma ® is designed to address the genetic root cause of SMA by providing a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression with a single, one-time IV infusion.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

The Pharma Data

MARCH 26, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. “We PD-L1 is a protein expressed on tumour cells and tumour-infiltrating cells, which suppresses the immune response and enables tumour cells to avoid detection by binding to proteins on the surface of immune cells.

Treatment 52

Treatment Therapies Protein Expression Immune Response 52

The Pharma Data

MAY 4, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. Tecentriq monotherapy has been shown to improve overall survival in people with high PD-L1 expression, when compared to chemotherapy, and therefore represents a new treatment option for people living with this difficult-to-treat disease.”.

Treatment 52

Treatment Therapies Disease Pharmaceuticals 52

The Pharma Data

JANUARY 13, 2021

GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021. CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. CHATHAM, N.J.,

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

JANUARY 13, 2021

The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. Aker BioMarine will supply the company with all its LPC product needs.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52

Codon

APRIL 9, 2023

AI + Bio *Transfer learning for cross-context prediction of protein expression from 5’UTR sequence. Read A roadmap to establish a comprehensive platform for sustainable manufacturing of natural products in yeast. Read Algal cell bionics as a step towards photosynthesis-independent hydrogen production. Subramanian M.

Therapies 52

Therapies RNA Engineering Vaccine 52

Conversations in Drug Development Trends

MAY 30, 2024

was withdrawn, rendering it unapproved for patient use, based on negative review comments by the Committee for Medicinal Products for Human Use. Other researchers are investigating approaches that use AAV-mediated trophic support and antibody-based therapies, such as vaccines and small molecule drugs, to modify various protein expressions.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

The Pharma Data

OCTOBER 26, 2020

Increased infiltrates, expression of immune related genes and higher PD-L1 protein expression were observed across all patients suggesting a remodeling of the tumor microenvironment consistent with a switch toward a “hot tumor” phenotype. Conclusions.

Vaccine 40

Vaccine Trials Treatment Virus 40